Interleukin-2 (IL-2) and T cell subpopulations were evaluated in children with rheumatic heart disease (RHD). Three groups were included: 13 patients with active RHD, 12 with non-active RHD, and 14 control children. Serum IL-2 and T cell subpopulations were measured by radioimmunoassay and monoclonal antibodies respectively.
There was a significant increase in IL-2 concentration with a significant decrease in CD8+ cells in patients with active RHD in comparison with the non-active group (mean (SEM) IL-2 of 3-48 (0.62) v 1-85 (0-24) U/ml and CD8+ of 23-75 (1-19) v 28-83 (1-91)%). Thus an increase in IL-2 and a decrease in CD8+ cells may be related to rheumatic activity. T helper (CD4+) cells did not differ significantly between groups.
(Arch Dis Child 1992;67:1373-5)
Interleukin-2 (IL-2) is a major lymphokine secreted by T cells after their stimulation with a mitogen or allergen.1 One of the cellular events Table 3 shows IL-2 concentrations in RHD (active and non-active) in comparison with controls. We found a significant increase of IL-2 in active RHD in comparison with controls. In a previous study IL-2 was found to increase the cell mediated cytotoxicity,12 while other investigators suggested the presence of cytotoxic cell species in patients with RHD that could be activated by streptococcal antigens leading to cellular damage during active rheumatic fever.'3 Those cells that have such cytolytic activity were found to be natural killer cells,'4 usually the activity of natural killer cells was found to be triggered by IL-2.'5 Data from these studies support the fact that the significant increase of IL-2 in the serum of our rheumatic patients means that IL-2 is important in the abnormal immune response in RHD via its effect on natural killer cell activity and the increase in cell mediated cytotoxicity. Also one of the abnormal immune responses that has been reported in RHD is the increased natural killer cell cytotoxicity.2 This observation can be explained by our findings of increased IL-2 production in rheumatic patients (p<001, table 3) as IL-2 is a lymphokine secreted from activated T lymphocytes and is responsible for the activity of natural killer cells, especially the cytotoxic character. 5 Thus we can suggest a sequence of events that is responsible for cellular damage in RHD: first stimulation of T lymphocytes by streptococcal antigens, this leads to secretion of IL-2, which results in increased natural killer cell cytotoxicity and the pathological changes in rheumatic patients.
In this study the Biotest Diagnostic Series of Clonab monoclonal antibodies (fluorochrome conjugated reagents for T cell typing) were used to determine T cell subsets in the studied groups of patients and controls. The CD3+, CD4+, and CD8+ monoclonal antibodies identify Active RHD Non-active RHD Controls (n= 13) (n= 12) (n= 14)
IL-2 (U/ml) respectively all mature peripheral blood T lymphocytes, helper T cells, and suppressor T cells.
The present study revealed that there was a significant decrease in CD8+ and CD3+ and significant increase in the H:S ratio in children with active RHD as compared with controls (p<0001, 0-01, 0-001, respectively, table 2). CD4+ cells showed a non-significant increase in the active group when compared with the controls (table 2) .
Other studies done on patients with acute rheumatic fever revealed significant depression of OKT1 + and OKT4+ with insignificant increase in OKT8+ cells. '6 Another in vitro study on tonsillar tissues from rheumatic patients revealed an increased CD4+ :CD8+ ratio after exposure to streptococcal products. 7 Our children with non-active RHD showed a significant decrease in CD3+ only (table 2, p<0(001), with no significant change in IL-2, CD4+, CD8+, and the H:S ratio. These results imply that deficient CD3+ can be considered a constant finding in RHD whether active or not.
By comparing active and non-active RHD we observed a significant increase in IL-2 and the H:S ratio with a significant decrease in CD8+ cells. Thus a constant increase of IL-2 and a decrease in CD8+ cells were observed in patients with active RHD in comparison with both controls (tables 2 and 3, respectively) and the non-active RHD group. These data may add another constant finding that is related to rheumatic activity.
CONCLUSION
Deficient CD3+ cells can be considered a constant finding in patients with RHD, whether active or non-active. Also the significant increase in serum concentrations of IL-2 and the significant decrease in CD8+ cells can be considered as a finding related to rheumatic activity. Finally another study has been planned to evaluate tumour necrosis factor-a, interleukin-I B (IL-IB), and natural killer cell function in active and non-active RHD.
